slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 7,051-7,080
Pages 395
Rows per page 30
Slide function
7,051-7,080 of 11,828
27
Data presented as % change from C1D1 Predose. Includes time course line chart and dot plot for maximum degradation.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
28
Data from a clinical study of KT-333, showing biomarker response across different dose levels (DL1, DL2, DL3).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
29
Includes ASH logo and specific clinical trial metrics (DL levels, AE types).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
30
The slide uses a split-layout: left side for clinical data results, right side for strategic positioning.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide combines a biological mechanism diagram with clinical trial data (table and line chart) to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
37
Swimmer plot showing days on study for three patients, with corresponding CT scan imagery for one patient.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
39
The slide uses a split-layout to contrast technical mechanism/data (left) with strategic market opportunity (right).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
04
The slide uses a two-column layout to contrast the current Phase 2 trial status with the upcoming OLE trial status.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
Data represents median and 25th/75th percentiles. Baseline values provided in footnotes.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
18
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
27
The charts display median values with 25th and 75th percentile error bars.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
30
The slide highlights the safety profile of the drug candidate, specifically noting the absence of serious adverse events and the nature of injection site reactions.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
34
The slide presents two visualizations: a dot plot with error bars for longitudinal data and a waterfall plot for individual subject response at Day 14.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
40
Kaplan-Meier survival curve showing efficacy of FXN replacement therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
41
The slide highlights key preclinical efficacy outcomes for the drug candidate CTI-1601.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
44
The slide uses two line charts to demonstrate efficacy in two different cardiac metrics (Ejection Function and Fractional Shortening) over an 8-week period.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
The chart uses a dual-axis approach to correlate margin expansion with ODR revenue growth.Limbach Holdings | Investor Presentation Deck | 28 slides · Limbach
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The slide uses stacked bar charts to show segment contributions (GCR vs ODR) and highlights year-over-year percentage growth.Limbach Holdings | Investor Presentation Deck | 28 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
23
The slide uses stacked bar charts to show segment performance (GCR vs ODR) and simple bar charts for EBITDA.Limbach Holdings | Investor Presentation Deck | 28 slides · Limbach
Pitch deck Investor relations Beat · Financials1 hit
11
Includes photos of the facility, battery packs, and assembly line.Lion Electric | Investor Presentation Deck | 30 slides · Lion Electric
Pitch deck Investor relations 1 hit
14
Includes a specific conditional order note at the bottom.Lion Electric | Investor Presentation Deck | 30 slides · Lion Electric
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
15
Includes photos of LION6 truck and LIONC school buses.Lion Electric | Investor Presentation Deck | 30 slides · Lion Electric
Pitch deck Investor relations 1 hit
11
This slide serves as a validation/traction point by highlighting a partnership with a major pharmaceutical company.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
13
The slide outlines a multi-part clinical trial process (Part A, Part B, and Expansion) for NSCLC 2L patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
17
Data presented in a table format with footnotes explaining the methodology for DCR calculation.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
24
Includes two line charts showing tumor volume reduction and rechallenge success.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
28
The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC models.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
29
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit